Head to Head Analysis: Phathom Pharmaceuticals (PHAT) and Its Peers

Phathom Pharmaceuticals (NASDAQ:PHAT) is one of 897 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Phathom Pharmaceuticals to related businesses based on the strength of its institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Valuation and Earnings

This table compares Phathom Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11 million	-$221.25 million	-4.86
Phathom Pharmaceuticals Competitors	$3.55 billion	$3.19 billion	545.56

Phathom Pharmaceuticals’ rivals have higher revenue and earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Phathom Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals’ rivals have a beta of -4.81, meaning that their average share price is 581% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Phathom Pharmaceuticals and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1	1	7	1	2.80
Phathom Pharmaceuticals Competitors	7750	13839	25668	1031	2.41

Phathom Pharmaceuticals presently has a consensus price target of $20.11, suggesting a potential upside of 223.33%. As a group, “Pharmaceuticals” companies have a potential upside of 26.24%. Given Phathom Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe Phathom Pharmaceuticals is more favorable than its rivals.

Profitability

This table compares Phathom Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%
Phathom Pharmaceuticals Competitors	-2,380.63%	-221.06%	-16.01%

Insider and Institutional Ownership

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Phathom Pharmaceuticals beats its rivals on 8 of the 12 factors compared.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.